Nifedipine is frequently used for patients who require an immediate reduction of blood pressure elevated temporarily by various administration techniques including sublingual route without administrating intravenous infusion of vasodilator. A cross-over clinical study was conducted to investigate the optimal administration metho of nifedipine for rapid management of hypertension. Four method of administering 10 mg nifedipine (the capsule was bitten and swallowed, sublingually with a hole in it or the contents administered orally or intranasally with a syringe) were evaluated with regarded e‹cacy, safety, and usefulness in 6 normal volunteers. Systolic and diastolic blood pressures were correlated with the nifedipine serum concentration in each method. Nifedipine pharmacokinetic parameters diŠered among the 4 administration methods. Nifedipine was absorbed rapidly by not only intestinal mucosa but also the nasal or oral mucosa. The pharmacological eŠect of intranasal or sublingual administration was superior. However, mint oil which is present in nifedipine capsules stimulates nasal mucosa when administered intranasally. For clinical usage, nifedipine capsules in which a hole is made with a needle, administered sublingually, can be eŠectively and safely used for rapid management of systemic hypertension.
INTRODUCTION
Nifedipine, a calcium channel blocking agent, is frequently used for the treatment of angina pectoris and hypertension. It is administered by various methods especially for pseudoemergency control of sudden and temporal increases in the blood pressure in Japan and European countries 1) although Grossman et al. 2) reported that sublingual administration of nifedipine might produce serious adverse eŠects. Although a method for administration of nifedipine for pseudoemergency antihypertensive treatment is described in the package insert of nifedipine products in Japan or some countries, it is actually administered by various techniques according to the custom of the ward or the judgment of the nurses while their eŠec-tiveness or safety remains unclear. A questionnaire survey of major medical institutions in Japan that we conducted revealed that the contents of capsule preparations have been administered sublingually or intranasally and that there are a number of problems with these administration methods; e.g., the dose is unsteady as the contents of a capsule are aspirated with a syringe, and the maneuver of puncturing the capsule using an injection needle is dangerous. 3) We carried out a clinical study of 4 methods of administration of the contents of nifedipine capsules frequently employed clinically to obtain a rapid reduction of elevated blood pressure in healthy adults. By evaluating the antihypertensive eŠect, pharmacokinetics, safety, and convenience of administration, we recommend an optimal method for nifedipine administration for pseudoemergency treatment.
METHODS

Preparation
Lemar(Kyorin Pharmaceutical Co., Ltd.) 10 mg soft capsules were used as a nifedipine preparation.
Subjects
The subjects were 6 healthy adult volunteers (4 males and 2 females) with a mean age of 25.3 years. Following approval of institutional ethical committee, the purpose of the study, nature of the test drug, testing methods, and expected side eŠects were explained to the subjects in advance orally and in writing, and their written consent was obtained. The subjects were selected according to the following criteria. (1) The subjects could participate in all 4 clinical studies. However, the subjects could at any time drop out from the study by their will. (2)
They are healthy individuals who had no disease, or past history of disease, of major organs including the heart, kidney, and liver.
3. Administration Methods Four methods of nifedipine administration commonly employed clinically in expectation of a rapid antihypertensive eŠect were selected. A: The contents of a capsule aspirated with a syringe is orally swallowed. B: A hole is made in a capsule, and the capsule is placed sublingually until it dissolves spontaneously. C: A capsule is broken by biting before it is swallowed (the method indicated in the package insert as a method that produces a rapid onset of action). D: The contents of a capsule aspirated in a syringe are administered intranasally.
Dose
Ten milligrams of nifedipine contained in 1 capsule was administered. However, 8.12 ±0.32 mg (Mean±SD, n＝6) was administered actually in administration A and D because it was unable to withdraw 100％ of the liquid contents from a capsule with a needle and syringe.
Testing Methods
A four-way cross-over study was performed with washout intervals of 2-3 weeks. The subjects were prohibited from taking any medication within 1 week before the test and administered the test drug after a 10-hour fast including abstention from alcoholic beverages. Clinical laboratory tests were performed before and after each test, and the absence of abnormalities in the blood proˆle, renal function, or hepatic function was conˆrmed. On the day of the test, all subjects were given the same meal (lunch).
6. Blood Sampling Blood samples were obtained at 13 points before and after (5, 10, 15, 20, 30, 45, 60, 90, 120, 240, 360 , and 480 min) the nifedipine administration, and the nifedipine concentration was measured. A heparin-locked indwelling needle was used until 120 min after the administration, and 5 ml of venous blood was collected at each point from the brachial vein. The samples obtained were placed in brown test tubes with aluminum foil covers, and were centrifuged (3,000 rpm, 20 min) promptly. The serum obtained was stored by freezing at -20°C until analysis.
Observation Items
The blood pressure (systolic, diastolic) and heart rate were measured before and every 5 min until 180 min after the administration and every 30 min thereafter until after 480 min. A household-use automatic sphygmomanometer (Omron HEM-703CP , oscillometric method) was used for the measurements.
Subjective symptoms and side eŠects were examined by the interviews of physician with the subjects and observation of changes in their condition (blush, perspiration, etc.).
Method for the Measurement of Serum Nifedipine Concentration
The external standard method of high-performance liquid chromatography published by Miyazaki et al. 4, 5) was evaluated, and analytical conditions were adjusted.
One milliliter of serum was mixed with 100 ml of methanol and 3 ml of acetonitrile, agitated with a vortex mixer, and centrifuged (3,000 rpm, 10 min), and serum was collected. Three milliliters of the serum was poured into a brown test tube containing 1 ml of distilled water, and 4.5 ml of a mixture of acetone and chloroform (1：1) was added. After the contents of the test tube were shaken and centrifuged for 10 min (3,000 rpm), the aqueous layer was removed, 5 ml of the organic layer was transferred to another brown test tube, and condensed to dryness in a centrifugal evaporator (VC-36, Taiyo Kagaku; heated to 45°C) over about 1 hour. The residue was dissolved with 100 ml of an external standard solution (Butanben 2 mg/ml), the solution wasˆltered, and 20 ml of theˆltrate was injected into the HPLC system. All these methods were performed under subdued light.
A LC-6A HPLC system (Shimadzu) and a SPD-6A UV detector (Shimadzu) were used. The analysis and assay of nifedipine were performed by warming the ODS reversed phase column (5C-18C, BENSIL; q4.6×150 mm) to 47°C in a column oven (CTO-6A, Shimadzu).
The mobile phase was a mixture of 0.01 M disodium hydrogen phosphate buŠer (pH 6.1) and methanol (52：48). The ‰ow rate was 0.8 ml/min, the detection wavelength was 238 nm, and the detection sensitivity was adjusted to 0.0025 a.u.f.s.
For preparation of a calibration curve, standard nifedipine solutions in methanol were prepared at 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, and 1.0 mg/ml. To drugfree serum, 100 ml each of the standard solutions was added instead of 100 ml of methanol, the mixtures were pretreated similarly to the samples, and a calibration curve was prepared. After the linearity of the calibration curve was conˆrmed, the samples were assayed by the two-point calibration line method using the 0.4 and 0.6 mg/ml nifedipine standard solutions.
Analytical Methods
For calculation of the values of pharmacokinetic parameters after the administration, analysis was performed by applying the data of serum concentration to a curve by the Simplex Method (non-linear least squares method), using the program of Pharmacokinetics Analysis and Graphics for Clinical Pharmacology (PAG-CP ) 6) developed by Takebe et al. The analysis was performed using the zero release of an oral administration 2-compartment model but using an oral administration, discontinuous absorption, 2-compartment model for administration method D (intranasal administration).
Statistical Analysis
Statistical analysis was performed by student paired t-test. The relationships between the mean nifedipine concentration and the mean systolic blood pressure (SBP) or the mean diastolic blood pressure (DBP) were analyzed by correlation analysis. Pharmacokinetics parameters were analyzed by ANOVA using Fisher PSLD. p＜0.05 was considered to be signiˆcant in all tests.
RESULTS
Serum Nifedipine Concentration
Linear regression analysis gave calibration curves with coe‹cient or correlation of 0.9991 ( p＜0.01) for nifedipine (0-1.0 mg/ml). Assays for within-run and day-to-day reproducibility gave coe‹cients of variation of 4.41％ (n＝6) and 21.46％ (n＝6), respectively, at concentrations of 0.6 mg/ml. The detection limit for quantiˆcation of this assay method was 5 ng/ml.
2. Changes in the Serum Nifedipine Concentration and Blood Pressure Figure 1 shows changes in the mean serum nifedipine concentration and blood pressure (systolic, diastolic) in the 6 subjects by administration method A, B, C, D until after 480 min. As the serum nifedipine concentration increased, SBP and DBP decreased in parallel, indicating a correlation between the serum nifedipine con- centration and the antihypertensive eŠect in each administration method. The correlation coe‹cients between the mean serum nifedipine concentration and the mean SBP and between the mean serum nifedipine concentration and the mean DBP in the 6 subjects were calculated by each administration method. The correlation coe‹cient between the nifedipine concentration and SBP was -0.539, and that between the nifedipine concentration and DBP was -0.575 ( p＜0.05), by method A. They were -0.427 and -0.502, respectively, by method B, -0.636 ( p＜ 0.05) and -0.781 ( p＜0.05), respectively, by method C, and -0.341 and -0.130, respectively, by method D (Figs. 2, 3) .
3. Pharmacokinetics of Nifedipine Figure 4 shows changes in the serum nifedipine concentration in 6 normal subjects by various administration methods. DiŠerences were observed in changes in the serum concentration (e.g. the pattern of changes until the peak concentration was reached and the duration of the peak concentration) among the 4 administration methods. Table 1 shows the values of pharmacokinetic parameters obtained by the analysis of the mean serum nifedipine concentration in the 6 subjects by each administration method. The area under the serum nifedipine concentration curve (AUC 0-∞ ) was 177.1 ±88.6 hr・ng/ml (mean±SE) by method A, being smaller ( p＜0.05) than by method B. The peak serum concentration (C max ) and the time until the peak serum concentration (T max ) also tended to be vary among the administration methods. C max was highest at 65.0±10.2 ng/ml by method C and lowest at 42.9 ±5.6 ng/ml by method D (intranasal administration). T max was shortest at 55.7±12.3 min by method D but slowest at 81.9±12.0 min by method C. The values of elimination half-life (T 1/2b ) and total cleasance (Clt) were in agreement with the values in the literature. Figure 5 shows changes in the mean serum nifedipine concentration in the 6 subjects until 30 min after the administration by the 4 methods. The mean serum concentration at 5 min was highest at 18.92± 12.84 ng/ml (mean±SD) by method D, showing the most rapid increase among the 4 methods, and remained highest until after 15 min. Following method D, the 5-min value was 11.46±6.71 ng/ml by method B, but the subsequent increase was gradual. At 5 min, which was theˆrst point of measurement, the serum nifedipine concentration showed signiˆcant diŠerences ( p＜0.05) by methods D and B compared with method A, indicating rapid increases in the serum concentration by these two methods. Figure 6 shows changes in the mean serum concentration, SBP, and DBP in the subjects until 30 min after the administration. The blood pressure was expressed as the diŠerence in the value at each point of measurement compared with the value before the administration. SBP and DBP decreased with the increases in the serum nifedipine concentration by each administration method. The diŠerences in the DBP among the administration methods were particularly notable. The serum concentration was highest until after 15 min by method D, the DBP also decreased signiˆcantly ( p＜0.05) and most notably among the 4 methods after 5-30 min after the administration. By method B, by which the increase in the serum concentration was the most rapid next only to method D, DBP at 5 min was D＝-7.2±9.8 mmHg, but its decreases until after 25 min were not signiˆcant. Figure 7 shows serial changes in the mean serum nifedipine concentration and DBP (diŠerence compared with the value before the administration: DDBP) in the 6 subjects by the administration methods. Concerning the relationship between the serum concentration and DDBP at 5 min, which re‰ects the quickness of the onset of the antihypertensive eŠect, they were both greatest at 18.92 ng/ml and -8.3 mmHg, respectively, by method D, followed by 11.46 ng/ml and -6.3 mmHg, respectively, by method B.
Serum Nifedipine Concentration and Antihypertensive EŠect
The heart rate, examined as a parameter of the eŠect, showed no signiˆcant or notable change by any administration method.
Side EŠects
Some subjects complained of mild headache, a heavy feeling of the head, blush, and a hot feeling during the test, but these symptoms were resolved within 2 hours after the end of the test. No serious side eŠects were observed.
DISCUSSION
Nifedipine is administered to obtain a rapid reduction of elevated suddenly and temporarily blood pressure for inpatients or hypertensive pseudoemergencies such as unstable hypertension, angina pectoris, or hypertension after surgery. [7] [8] [9] [10] [11] The``Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure'' recognize that parenteral drugs for treatment of hypertensive emergencies are vasodilators, such as sodium nitroprusside and nitroglycerin. 12) Grossman et al. 2) reported that sublingual nifedipine capsule given for hypertensive emergencies might produce severe adverse eŠects such as cerebrovascular ischemia, stroke, hypotension, acute myocardial infarction and death. However, nifedipine is still widely used for treatment of emergency, especially pseudoemergency hypertension, because it has been said that it has rarely induced excessive hypotension and has had no serious side eŠects. 13) Brown et al. 14) compared sublingual administration of nifedipine with oral administration and reported that the increase in the serum nifedipine concentration was more rapid by the sublingual administration. On the other hand, there have been reports that nifedipine was not almost absorbed through the oral mucosa, and sublingual nifedipine was not eŠective. 15, 16) It was reported that intranasal administration of nifedipine was also eŠective 17) although the intranasal absorption was not inspected su‹ciently. Comparative studies of changes in the serum nifedipine concentration and diŠerences in the antihypertensive eŠect among oral administration and various types of sublingual administration have been carried out to date, but contradicting results have been reported. Additionally, comparative studies of sublingual and intranasal administration have not been reported.
Aoki et al. [18] [19] [20] reported that the serum nifedipine concentration correlated closely with the blood pressure in patients with hypertension orally administered nifedipine. Nifedipine usually shows no marked antihypertensive eŠect in normal individuals, because the diastaltic sympathicotonia through pressoreceptor with decreases of peripheral arterial resistance induces the increases of heart rate, and prevents blood pressure decreases. 20) However, there have been reports [21] [22] [23] [24] [25] [26] [27] [28] that nifedipine signiˆcantly reduced the blood pressure by oral and sublingual administration and that the serum nifedipine concentration was correlated with the antihypertensive eŠect in normal individuals. In our study, also, the serum concentration was correlated with blood pressure, especially DBP, by each administration method. The serum concentration of nifedipine has been reported to be correlated more closely with DBP than with SBP. 18) Thus, the serum concentration and blood pressure are parameters useful for e‹cacy evaluation. Changes in the serum concentration of nifedipine are considered to be useful information for the judgment of its antihypertensive eŠect particularly in normal individuals.
Changes in the serum nifedipine concentration and blood pressure until 30 min after the administration also diŠered according to the administration method. By method D, by which the serum nifedipine concentration 5 min after the administration was highest among the 4 methods, DBP showed signiˆcant and largest decreases from after 5 min. DBP decreased after 5 min also by method B, by which the increase after the administration was the fastest next only to method D. The changes in heart rates were not observed because blood pressure decreased signiˆcantly though the degree of antihypertensive eŠect was low. From the serum concentration and antihypertensive eŠect 5 min after the administration, the method D is expected to produce the most rapid onset of the antihypertensive eŠect, followed by method B.
It was reported that nifedipine was not absorbed su‹ciently through the oral mucosa, however, it was indicated that nifedipine was absorbed partly through the oral and nasal mucosa in this study. According to Waller et al., 29) nifedipine is likely to undergoˆrst-pass metabolism in the gastrointestinal wall. Also, the drug concentration and absorption rate at the absorption site are estimated to vary according to the administration method.
By method A, i.e. swallowing the contents of the capsule aspirated with a syringe, the drug directly reaches the absorption site in the gastrointestinal tract. However, there is a time lag until the beginning of absorption, and the drug may be aŠected byˆrst-pass metabolism in the gastrointestinal tract. Moreover, the dose is uncertain, because the small contents of the capsule is aspirated with a syringe.
By method C, the capsule was swallowed after breaking it by biting. Therefore, absorption of nifedipine through the oral mucosa is expected, but absorption begins mostly after the drug reaches the gastrointestinal tract. Therefore, the time lag until the beginning of absorption is large, and the drug is liable tô rst-pass metabolism. These factors are considered to have been involved together in the low nifedipine concentration in the initial phase. Furthermore, some nifedipine soft capsule products are relatively hard and di‹cult to break by biting. Therefore, the administration by this method is considered to be di‹cult in such patients as those exhibiting acute symptoms of myocardial infarction, those with reduced level of consciousness, and elderly patients.
Nifedipine absorbed through the oral mucosa or nasal mucosa enters the systemic circulation without passing the portal system so that it escapesˆrst-pass metabolism. Also, in mucosal absorption, the absorption rate is generally considered to be fast. These are considered to be reasons for the rapid increase in the serum nifedipine concentration in the initial phase by administration methods B and D.
By method D, i.e. intranasal administration, the actual dose tends to be unsteady, and the bioavailability is low. Also, the drug is retained in the nasal cavity and is absorbed through the mucosa, but part of it ‰ows into the gastrointestinal tract via the internal nares and pharynx. Therefore, the serum nifedipine concentration shows several peaks, and the whole pharmacokinetics is unclear. The results of this study suggest that the increase in the serum concentration early after the administration and the eŠect of a reduction in blood pressure were the best by this method among the 4 methods. However, the greatest problem with intranasal administration of nifedipine using currently available commercial preparations is irritation of the nasal mucosa by the mint oil compounded as a corrigent, which causes great discomfort to patients.
By method B, i.e. making a needle hole in the capsule and placing the capsule sublingually, which showed the most rapid increase in the serum nifedipine concentration next only to method D, the drug ‰ows out gradually from the capsule placed sublingually and is absorbed partly through the oral mucosa but is also considered to be absorbed partly through the gastrointestinal tract. Also, the method is advantageous for sustaining a stable serum concentration, because absorption progresses gradually so that frequent repetition of administration may be avoided. However, there is the risk of injuring theˆngers during puncture of the capsule with a needle. From the pharmacokinetics, the eŠect of a reduction in blood pressure, safety and ease of administration, sublingual administration of a capsule preparation after making a needle hole is considered to be clinically the most recommendable for the administration of nifedipine to obtain a rapid onset of eŠect. Close clinical monitoring is indicated until 30 min after administration of nifedipine. However, the development of dosage forms and preparations catering to clinical needs and evaluation of safer and more eŠective administration methods are considered to be necessary. 
